Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$38.49 USD

38.49
5,224,019

-0.27 (-0.70%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $38.50 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

3 Medical Device Stocks with Solid Potential to Buy Now

The Medical Device industry has been riding high on optimism of late, courtesy of the Senate's latest decision to lacerate the Affordable Care Act (ACA) by the end of July.

    Baxter International (BAX) Up 6.7% Since Earnings Report: Can It Continue?

    Baxter International (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne

      Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne

        Quest Diagnostics Poised on Solid Q1 Results Despite Woes

        On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.

          Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint

          Medtronic plc (MDT) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent.

            Tirthankar Chakraborty headshot

            5 Top Efficient Stocks to Add to Your Portfolio

            We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

              Edwards Lifesciences SAPIEN 3 Heart Valve Data Positive

              Edwards Lifesciences Corporation (EW) recently unveiled positive one-year data on its SAPIEN 3 transcatheter heart valve.

                TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1

                TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.

                  Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up

                  Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.

                    Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite

                    Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.

                      STERIS (STE) Grapples with Headwinds: Should You Dump?

                      On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.

                        Tirthankar Chakraborty headshot

                        New Strong Buy Stocks for May 12th

                        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

                          Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View

                          Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.

                            Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates

                            Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.

                              Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip

                              On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.

                                Becton (BDX) Announces $4.5B Follow-On Share Offerings

                                Becton, Dickinson and Company (BDX), popularly known as BD, recently announced a follow-on offering of $4.5 billion for its shares.

                                  STERIS (STE) Tops Q4 Earnings & Revenues, Issues '18 View

                                  STERIS Plc (STE) reported fourth-quarter fiscal 2017 adjusted earnings per share (EPS) of $1.11, up 23.3% from the year-ago quarter.

                                    Penumbra (PEN) Q1 Loss Wider than Expected, View Intact

                                    Penumbra, Inc. (PEN), that went public in Sep 2015, reported first-quarter 2017 loss of 10 cents per share, comparing unfavorably with earnings of 7 cents year over year.

                                      PetMed (PETS) Beats Earnings, Revenue Estimates in Q4

                                      PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.

                                        Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View

                                        Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.

                                          Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View

                                          Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.

                                            Phibro (PAHC) Posts In Line Earnings in Q3, Revises View

                                            Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 37 cents in the third quarter of fiscal 2017, down 7.5% year over year.

                                              Align Technology Invisalign Sales Strong, Currency Woes Stay

                                              On May 5, we issued an updated research report on Align Technology (ALGN), which manufactures a system of clear aligner therapy.

                                                Qiagen Banks on Molecular Diagnostic amid Currency Woes

                                                On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).

                                                  CVS Down on Weak Earnings, Pharmacy Services Remains Strong

                                                  On May 5, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).